Kornitzer Capital Management Inc. KS Invests $921,000 in LeMaitre Vascular, Inc. $LMAT

Kornitzer Capital Management Inc. KS bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 11,090 shares of the medical instruments supplier’s stock, valued at approximately $921,000.

Other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its holdings in LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier’s stock worth $9,385,000 after buying an additional 3,248 shares during the period. US Bancorp DE raised its holdings in shares of LeMaitre Vascular by 36.0% during the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock valued at $117,000 after acquiring an additional 368 shares during the period. Northern Trust Corp lifted its position in shares of LeMaitre Vascular by 5.4% in the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after acquiring an additional 17,748 shares in the last quarter. Congress Asset Management Co. boosted its stake in LeMaitre Vascular by 4.6% in the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock worth $55,973,000 after purchasing an additional 29,553 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in LeMaitre Vascular during the 2nd quarter worth approximately $892,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer directly owned 1,727,003 shares in the company, valued at $161,492,050.53. This trade represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 10,815 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. This trade represents a 37.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock valued at $11,280,206 over the last three months. 9.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Barrington Research reissued an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Saturday. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus target price of $97.60.

LeMaitre Vascular Trading Up 0.2%

LeMaitre Vascular stock opened at $89.21 on Monday. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.02 billion, a P/E ratio of 43.31, a P/E/G ratio of 2.30 and a beta of 0.77. The company’s fifty day simple moving average is $91.31 and its 200-day simple moving average is $86.79.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $63.15 million during the quarter, compared to analysts’ expectations of $62.48 million. During the same quarter last year, the firm earned $0.52 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a $0.20 dividend. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is currently 38.83%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.